Yıl: 2021 Cilt: 28 Sayı: 7 Sayfa Aralığı: 1417 - 1422 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2020.07.712 İndeks Tarihi: 07-11-2021

Expression level of UCMA as a candidate molecular targetin osteoarthritis

Öz:
Aim: Osteoarthritis (OA) is a degenerative joint disorder that damages cartilage, synovium and subchondral bone, and there is yet no effective treatment for OA. The identification of novel therapeutic methods is crucially needed for better treatment of OA. Upper zone of growth plate and cartilage matrix associated (UCMA) was discovered as a chondrocyte specific protein in 2008, but its expression is solely not specific to cartilage tissue. Although UCMA is implicated in cartilage and bone metabolic processes, the molecular function of UCMA in OA is not elucidated yet. We aimed to examine the potential effect of UCMA in osteoblast metabolism associated with OA. Materials and Methods: We created an in vitro OA model by inducing osteoblast cell line with IL-1β. The expression levels of 12 related genes were determined using the qRT-PCR method. The MMP1 and OPG expression levels in the supernatants of cells were detected with ELISA. Results: We found that there was a dramatic increase in the levels of UCMA expression and other OA-related markers. We showed that IL-1β triggered the expression of main transcription factors playing a role during bone formation. MMP1 and OPG synthesis and secretions were increased in IL-1β induced-hFOB1.19 cell line significantly. Conclusion: Our study, as the first one using the human osteoblast cell line, provides good evidence about the potential value of UCMA in the pathophysiology of OA and shows that UCMA can be a promising molecular target to develop therapeutic approaches for OA.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1. Hosnijeh FS, Runhaar J, van Meurs JB, et al. Biomarkers for osteoarthritis: Can they be used for risk assessment? A systematic review. Maturitas 2015;82:36-49.
  • 2. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249-57.
  • 3. Kirwan JR, Elson CJ. Is the progression of osteoarthritis phasic? Evidence and implications. J Rheumatol 2000;27:834-6.
  • 4. Kraus VB, Blanco FJ, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage 2015;23:1233-41.
  • 5. Kwan Tat S, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70.
  • 6. Findlay DM, Atkins GJ. Osteoblast-chondrocyte interactions in osteoarthritis. Curr Osteoporos Rep 2014;12:127-34.
  • 7. Maruotti N, Corrado A, Cantatore FP. Osteoblast role in osteoarthritis pathogenesis. J Cell Physiol 2017;232:2957-63.
  • 8. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
  • 9. Kwan Tat S, Pelletier JP, Lajeunesse D, et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008;26:295- 304.
  • 10. Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol 2013;45:2580-4.
  • 11. Kwan Tat S, Padrines M, Theoleyre S, et al. IL6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.
  • 12. Price PA, Williamson MK, Haba T, et al. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci U S A 1982;79:7734-8.
  • 13. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
  • 14. Neacsu CD, Grosch M, Tejada M, et al. Ucmaa (Grp2) is required for zebrafish skeletal development. Evidence for a functional role of its glutamate gammacarboxylation. Matrix Biol 2011;30:369-78.
  • 15. Misra D, Booth SL, Tolstykh I, et al. Vitamin K deficiency is associated with incident knee osteoarthritis. Am J Med 2013;126:243-8.
  • 16. Cancela ML, Conceicao N, Laize V. Gla-rich protein, a new player in tissue calcification? Adv Nutr 2012;3:174-81.
  • 17. Okuyan HM, Terzi MY, Ozcan O, et al. Association of UCMA levels in serum and synovial fluid with severity of knee osteoarthritis. Int J Rheum Dis 2019;22:1884- 90.
  • 18. Okuyan HM, Ozcan O, Dogan S, et al. Upper Zone of Growth Plate and Cartilage Matrix (UCMA) levels in patients with chronic kidney disease. Brazilian Archives of Biology and Technology 2020;63.
  • 19. Viegas CS, Simes DC, Laize V, et al. Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem 2008;283:36655-64.
  • 20. Liu YZ, Jackson AP, Cosgrove SD. Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage 2009;17:1333-40.
  • 21. Fuerst M, Bertrand J, Lammers L, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009;60:2694-703.
  • 22. O'Connell JX. Pathology of the synovium. Am J Clin Pathol 2000;114:773-84.
  • 23. Hernandez-Santana A, Yavorskyy A, Loughran ST, et al. New approaches in the detection of calciumcontaining microcrystals in synovial fluid. Bioanalysis 2011;3:1085-91.
  • 24. Ea HK, Nguyen C, Bazin D, et al. Articular cartilage calcification in osteoarthritis: insights into crystalinduced stress. Arthritis Rheum 2011;63:10-8.
  • 25. Stock M, Menges S, Eitzinger N, et al. A dual role for UCMA in osteoarthritis-Inhibition of aggrecanases and promotion of bone turnover. Arthritis Rheumatol 2017; 69:1233-45.
  • 26. Cavaco S, Viegas CS, Rafael MS, et al. Gla-rich protein is involved in the cross-talk between calcification and inflammation in osteoarthritis. Cell Mol Life Sci 2016;73:1051-65.
  • 27. Viegas CS, Rafael MS, Enriquez JL, et al. Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. Arterioscler Thromb Vasc Biol 2015;35:399-408.
  • 28. Eitzinger N, Surmann-Schmitt C, Bosl M, et al. Ucma is not necessary for normal development of the mouse skeleton. Bone 2012;50:670-80.
  • 29. Surmann-Schmitt C, Dietz U, Kireva T, et al. Ucma, a novel secreted cartilage-specific protein with implications in osteogenesis. J Biol Chem 2008;283:7082-93.
  • 30. Sun J, Li J, Li C, et al. Role of bone morphogenetic protein-2 in osteogenic differentiation of mesenchymal stem cells. Mol Med Rep 2015;12:4230-7.
  • 31. Lysdahl H, Baatrup A, Foldager CB, et al. Preconditioning Human Mesenchymal Stem Cells with a Low Concentration of BMP2 Stimulates Proliferation and Osteogenic Differentiation In Vitro. Biores Open Access 2014;3:278-85.
  • 32. Lee YJ, Park SY, Lee SJ, et al. Ucma, a direct transcriptional target of Runx2 and Osterix, promotes osteoblast differentiation and nodule formation. Osteoarthritis Cartilage 2015;23:1421-31.
  • 33. Garcia-Reyero N, Escalon L, Prats E, et al. Targeted Gene Expression in Zebrafish Exposed to ChlorpyrifosOxon Confirms Phenotype-Specific Mechanisms Leading to Adverse Outcomes. Bull Environ Contam Toxicol 2016;96:707-13.
  • 34. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal 2009;3:311-22.
  • 35. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
  • 36. Castaneda S, Roman-Blas JA, Largo R, et al. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012;83:315-23.
  • 37. Kwan Tat S, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009;48:1482-90.
  • 38. Trouvin AP, Goeb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010;5:345-54.
  • 39. Martin TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop 2013;4:186-97.
APA OKUYAN H, Arslan A, IĞCI Y, GÖĞEBAKAR B, ERCİN N, GÜNDÜZ K, Sonmez D (2021). Expression level of UCMA as a candidate molecular targetin osteoarthritis. , 1417 - 1422. 10.5455/annalsmedres.2020.07.712
Chicago OKUYAN HAMZA MALİK,Arslan Ahmet,IĞCI Yusuf Ziya,GÖĞEBAKAR Bulent,ERCİN Nilufer,GÜNDÜZ Kübra,Sonmez Dilara Expression level of UCMA as a candidate molecular targetin osteoarthritis. (2021): 1417 - 1422. 10.5455/annalsmedres.2020.07.712
MLA OKUYAN HAMZA MALİK,Arslan Ahmet,IĞCI Yusuf Ziya,GÖĞEBAKAR Bulent,ERCİN Nilufer,GÜNDÜZ Kübra,Sonmez Dilara Expression level of UCMA as a candidate molecular targetin osteoarthritis. , 2021, ss.1417 - 1422. 10.5455/annalsmedres.2020.07.712
AMA OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D Expression level of UCMA as a candidate molecular targetin osteoarthritis. . 2021; 1417 - 1422. 10.5455/annalsmedres.2020.07.712
Vancouver OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D Expression level of UCMA as a candidate molecular targetin osteoarthritis. . 2021; 1417 - 1422. 10.5455/annalsmedres.2020.07.712
IEEE OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D "Expression level of UCMA as a candidate molecular targetin osteoarthritis." , ss.1417 - 1422, 2021. 10.5455/annalsmedres.2020.07.712
ISNAD OKUYAN, HAMZA MALİK vd. "Expression level of UCMA as a candidate molecular targetin osteoarthritis". (2021), 1417-1422. https://doi.org/10.5455/annalsmedres.2020.07.712
APA OKUYAN H, Arslan A, IĞCI Y, GÖĞEBAKAR B, ERCİN N, GÜNDÜZ K, Sonmez D (2021). Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research, 28(7), 1417 - 1422. 10.5455/annalsmedres.2020.07.712
Chicago OKUYAN HAMZA MALİK,Arslan Ahmet,IĞCI Yusuf Ziya,GÖĞEBAKAR Bulent,ERCİN Nilufer,GÜNDÜZ Kübra,Sonmez Dilara Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research 28, no.7 (2021): 1417 - 1422. 10.5455/annalsmedres.2020.07.712
MLA OKUYAN HAMZA MALİK,Arslan Ahmet,IĞCI Yusuf Ziya,GÖĞEBAKAR Bulent,ERCİN Nilufer,GÜNDÜZ Kübra,Sonmez Dilara Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research, vol.28, no.7, 2021, ss.1417 - 1422. 10.5455/annalsmedres.2020.07.712
AMA OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research. 2021; 28(7): 1417 - 1422. 10.5455/annalsmedres.2020.07.712
Vancouver OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D Expression level of UCMA as a candidate molecular targetin osteoarthritis. Annals of Medical Research. 2021; 28(7): 1417 - 1422. 10.5455/annalsmedres.2020.07.712
IEEE OKUYAN H,Arslan A,IĞCI Y,GÖĞEBAKAR B,ERCİN N,GÜNDÜZ K,Sonmez D "Expression level of UCMA as a candidate molecular targetin osteoarthritis." Annals of Medical Research, 28, ss.1417 - 1422, 2021. 10.5455/annalsmedres.2020.07.712
ISNAD OKUYAN, HAMZA MALİK vd. "Expression level of UCMA as a candidate molecular targetin osteoarthritis". Annals of Medical Research 28/7 (2021), 1417-1422. https://doi.org/10.5455/annalsmedres.2020.07.712